Leukemia Therapeutics Market Forecast 2024-2033: Projected CAGR, Key Drivers, And Trends

Overview and Scope
Leukemia therapeutics refer to a treatment used to treat an aggressive (quickly spreading) malignancy in which the blood or bone marrow contain an excessive amount of myeloblasts (immature white blood cells). The type treatment for leukemia depends on various factors such as age, overall health, type of leukemia, its current condition within the body and others.

Sizing and Forecast
The leukemia therapeutics market size has grown strongly in recent years. It will grow from $16.55 billion in 2023 to $17.78 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to growth in geriatric population, improved diagnostics leading to early detection of leukemia, increasing prevalence of leukemia, growing investment in research and development, expansion of personalized medicine approaches..

The leukemia therapeutics market size is expected to see strong growth in the next few years. It will grow to $23.98 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to development of novel immunotherapies for leukemia, growing focus on precision medicine in leukemia treatment, expansion of indications for existing leukemia therapies, increased adoption of gene therapies,
advances in supportive care for leukemia patients. Major trends in the forecast period include integration of biomarker-driven approaches, rise of combination therapies for enhanced efficacy, emphasis on minimal residual disease monitoring, increasing use of car-t cell therapies, exploration of targeted therapies based on leukemia subtypes.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Segmentation & Regional Insights
The leukemia therapeutics market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments
2) By Type Of Leukemia: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Type Of Leukemia
3) By Molecule Type: Small Molecules, Biologics
4) By End-Users : Hospitals, Homecare, Specialty Clinics, Other End-Users

North America was the largest region in the leukemia therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6358&type=smp

Major Driver Impacting Market Growth
The rising prevalence of leukemia is driving the growth of the leukemia therapeutics market. Leukemia is a type of blood cancer that starts in the bone marrow and proceeds to uncontrolled blood cell growth. The increased accessibility of medical treatment to leukemia patients across the globe and the growing availability of treatment options have contributed to increased demand for leukemia therapeutics. For instance, in January 2023, according to a report published by the American Cancer Society, a US-based health organization, it is anticipated that there will be around 59,610 new instances of leukemia of all types and approximately 23,710 fatalities in 2023 resulting from leukemia of all types in the United States. Additionally, an estimated 20,380 new cases of acute myeloid leukemia (AML) and about 11,310 AML-related deaths are expected in the same year. Therefore, the rising prevalence of leukemia is contributing to the growth of the leukemia therapeutics market.

Key Industry Players
Major companies operating in the leukemia therapeutics market report are Novartis International AG, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Sanofi S. A., Agios Pharmaceuticals, Amgen Inc., Argenx SE, Astellas Pharma Inc., BioLineRx Ltd., Celgene Corporation, Cellerant Therapeutics Inc., Daiichi Sankyo Company Limited, Forma Therapeutics Inc., Gilead Sciences Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson, Mirati Therapeutics Inc., Molecular Templates Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Seattle Genetics Inc., Stemline Therapeutics Inc., Sunesis Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, TG Therapeutics Inc., Trovagene Inc., Akebia Therapeutics Inc., Allogene Therapeutics Inc., Blueprint Medicines Corporation, Karyopharm Therapeutics Inc., Verastem Oncology Inc.

The leukemia therapeutics market report table of contents includes:

1. Executive Summary

2. Leukemia Therapeutics Market Characteristics

3. Leukemia Therapeutics Market Trends And Strategies

4. Leukemia Therapeutics Market – Macro Economic Scenario

5. Global Leukemia Therapeutics Market Size and Growth
.
.
.

31. Global Leukemia Therapeutics Market Competitive Benchmarking

32. Global Leukemia Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Leukemia Therapeutics Market

34. Leukemia Therapeutics Market Future Outlook and Potential Analysis

35. Appendix

Top Major Players:

Novartis International AG

AbbVie Inc

F. Hoffmann-La Roche AG

Sanofi S. A.

Agios Pharmaceuticals

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info 

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company 
Twitter: https://twitter.com/tbrc_info 
Facebook: https://www.facebook.com/TheBusinessResearchCompany 
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ 
Blog: https://blog.tbrc.info/ 
Healthcare Blog: https://healthcareresearchreports.com/ 
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model